Galmed Pharmaceuticals

Next Generation of Metabolic and Inflammatory Therapeutics

Health Tech & Life Sciences
Public on NASDAQ on Mar 2014
Follow

Company Overview

Snapshot

Founded in January 2000, Galmed Pharmaceuticals operates with 1–10 employees and has raised a total of $150.3 million across 5 public offerings. The company was publicly listed on NASDAQ in March 2014, marking a significant milestone in its growth.

Business overview

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases. Its core product, Aramchol, is a lead compound currently undergoing a Phase 3 registrational study for the treatment of NASH and fibrosis. The company also collaborates with the Hebrew University on Amilo-5MER, a 5-amino acid synthetic peptide, and recently initiated a first-in-human study for this compound. Galmed operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and biotechnology markets.

Strategic signal

In June 2026, Galmed Pharmaceuticals announced its acquisition of Colospan, signaling a strategic expansion into a GI-focused platform targeting a multi-billion dollar market. This move indicates Galmed's intent to diversify its therapeutic areas beyond its current focus on liver and metabolic diseases, positioning the company for broader market reach and potential revenue growth.

Log in to access full profile ›

Company Intelligence Q&A

What was a significant recent strategic move by Galmed Pharmaceuticals?
In June 2026, Galmed Pharmaceuticals announced its acquisition of Colospan, aiming to create a GI-focused platform targeting a $6 billion market.
What were the results of the AM-001 study of Aramchol Meglumine?
In November 2025, Galmed announced meaningful top-line results from the AM-001 study of Aramchol Meglumine.
What was reported regarding Aramchol's anti-fibrotic effects in PSC models?
In May 2025, Galmed reported significant anti-fibrotic effects of Aramchol in Primary Sclerosing Cholangitis (PSC) models.
What was the outcome of the first-in-man pharmacokinetics study of oral Aramchol Meglumine?
In May 2026, Galmed announced results showing that 400mg of Aramchol Meglumine increased bioavailability by approximately 500% compared to 300mg of Aramchol Free Acid.
When did Galmed Pharmaceuticals file its annual report for the fiscal year 2025?
In March 2026, Galmed Pharmaceuticals Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.
Log in to access full profile ›

External links